SYNTHOS RESEARCH

Broadridge Financial Solutions BR

Technology · Information Technology Services · Synthos Deep Dive · 2026-07-03

$143.95
Watch
Risk 4Growth 6Exponential 3Fair value $187 $120–$240

At a glance

VerdictWatch — systematic Synthos tier
Price (2026-07-02)$143.95 · market cap ~$16.6B
Synthos scores (0–10)Downside Risk 4 · Growth Quality 6 · Exponential Potential 3
Synthos fair value (base case)~$187+30% · full range $120 (bear) – $240 (bull)
Street consensus$210 (high $257 / low $165; 15 Buy · 9 Hold · 0 Sell) — context, not our anchor
Valuation15.3× trailing EPS · ~15× FY26E · 14× FY27E · 10× FY30E · EV/S 2.7× · EV/EBITDA 10.0×
Exponential Potential3/10 · Low — high-single-digit recurring growth is steady, not accelerating; a mature niche processor, not a next-exponential
TechnicalsDowntrend — $143.95, −46% off 52-wk high, below 50/200-DMA, RSI 49, −41% 12-mo (SPY +21%)
ConvictionLow breadth — 0 expert voices, 0 KB claims. This is a quant/fundamental call, stated plainly.
Position sizingSatellite value/quality, ~1.5–3%, scaled in — the falling knife has not clearly bottomed
Next catalyst2026-08-04 FY26 Q4 earnings (Street EPS $3.76, rev ~$2.17B)
Single biggest riskThe re-rating isn't over — a steady 10–12% EPS grower can keep de-rating if the market decides "utility, not growth"

One-line thesis. Broadridge is a deeply entrenched financial-market infrastructure processor (proxy/investor communications + trade processing) that just fell ~46% from its high while the business kept compounding — FY25 revenue $6.89B (+5.9%), 40% ROE, ~$1.06B free cash flow, and management raising FY26 adjusted-EPS-growth guidance to 10–12%. The stock now trades at ~15× forward earnings, cheap for its durability, but with zero expert coverage in our KB this is a value-quality call carried entirely by the numbers — and the chart says the market is still repricing it.

◆ Synthos call — Watch BR is a business we want at a price we don't have — it becomes a Buy below ~$192; until then, do nothing.
Downside Risk (lower = safer)
4/10 · Moderate
Low beta (0.90), sticky recurring revenue, modest 1.6× net-debt/EBITDA — but a −46% drawdown shows a re-rating already underway.
Growth Quality
6/10 · High
High-single-digit recurring-revenue growth, low-teens EPS CAGR, 40% ROE, but revenue growth is steady-not-accelerating.
Exponential Potential
3/10 · Low
A mature ~$17B compounder in a slow-growth utility-like niche; tokenization/AI optionality is real but small vs the base.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 13%/yr To justify today’s $144, earnings would have to compound roughly 13% a year for 10 years (9% discount rate). Analysts forecast ~10%/yr, so the market is pricing in MORE than what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Broadridge is a behind-the-scenes plumbing company for Wall Street. When you own a stock or mutual fund, someone has to mail (or email) you the proxy vote, the annual report, and the tax forms, and someone has to process the trades banks make — Broadridge is that someone, for most of the industry. It gets paid steady, recurring fees to do boring, essential work that's very hard to switch away from.

The business is doing fine — sales and profits keep grinding higher every year, and it earns a very high return on the money shareholders put in. But the stock got cut almost in half over the past year, from about $272 down to $144. Nothing catastrophic happened to the company; the market simply decided it had paid too high a price and marked it down. That's why it now looks reasonably cheap relative to how much it earns.

Our verdict is Buy — Tactical: a decent-value buy in a solid, dull, cash-generating company — but "tactical," not "core," because (1) no outside experts we track are on record championing it, and (2) a stock in a clear downtrend can keep falling before it turns.

Here's what our three scores mean in everyday terms:

The one big worry: the market may keep re-pricing a slow-and-steady grower downward, so even a cheap-looking, well-run company can stay cheap or get cheaper for a while.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

125163201239277Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $267200-DMA 19250-DMA 148Price 14452w lo $135

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

119160202243284Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26Price 14420-day avg 142

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 50.5

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 51.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26MACD -3.1signal -3.6

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago

4978107135164Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26XLK (sector) 142S&P 500 120BR 60

Solid = BR · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

025710$6BFY23EPS $7$6BFY24EPS $6$7BFY25EPS $8$7BFY26EEPS $10$8BFY27EEPS $10$8BFY28EEPS $11$8BFY29EEPS $13$9BFY30EEPS $14

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$143.95
Market cap$17B
P/E trailing
P/E FY26E / FY27E15× / 14×
EV / Sales2.7×
EV / EBITDA10.0×
Gross margin31.3%
Net margin15.0%
Dividend yield2.71%
Beta0.903
52-wk range$135 – $267
RSI(14)49
50 / 200-DMA$148 / $192
12-mo return+-41% (SPY +21%)
Street target$210 ($165–$257)
Analyst grades15 Buy · 9 Hold · 0 Sell
FMP ratingA-
Next earnings2026-08-05

What the experts actually said 0 traceable claims on BR · showing the highest-conviction voices

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Broadridge Financial Solutions (NYSE: BR) is a ~$17B-market-cap financial-technology and communications company spun out of ADP in 2007, headquartered in Lake Success, NY, with ~14,000 employees. Its fiscal year ends June 30. It operates the essential, largely invisible infrastructure of the securities industry across two reportable segments:

Revenue mix (FY2025, from filings):

The strategic story management is pushing (§9): democratize/digitize governance, modernize wealth management, and lean into tokenization (it powered the first on-chain US public-company proxy vote and processes $354B/day on a distributed-ledger repo platform) and AI (agentic AI driving ~25% efficiency gains in its managed services).

2. The expert thesis (traceable)

There is no expert coverage for BR in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top claims array is empty. No independent voice we track — bullish or bearish — is on record on this name.

Per the Synthos house standard, that fact is stated plainly rather than papered over: this verdict carries no conviction-track weight. Everything below is derived from the fundamentals (FMP financials), analyst consensus estimates (labeled as estimates), and management's own guidance (half-weighted, §9). Readers should treat this as a quant/fundamental note, not an expert-panel note. Where a name like Eli Lilly earns a High conviction rating from 13 reconciled voices, BR earns none — and we will not manufacture one.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)4 · Below-average riskBeta 0.90, sticky recurring revenue, net-debt/EBITDA 1.6×, interest coverage 11×, investment-grade (rating A-). Offsetting: a −46% drawdown proves sentiment can re-rate it hard, and it's still below both moving averages.
Growth Quality6 · Solid~7% recurring-revenue growth (constant currency), ~10–12% adjusted-EPS growth guided, 40% ROE, 13% ROIC, 31% gross / 27% EBITDA margins. High quality, but the growth rate itself is only moderate and not accelerating.
Exponential Potential3 · LowA mature ~$17B processor in a slow-growth, utility-like niche. Revenue growth is steady in the mid-to-high single digits with a negative second derivative vs the post-COVID years. Tokenization/AI optionality is real but tiny vs the base.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. (EPS below are FMP consensus estimates, labeled as estimates.)

CaseKey assumptionsFair value
BullRecurring growth reaccelerates toward 8%+, closed sales convert, tokenization/AI adds a visible new revenue leg; the market re-rates BR back toward its historical ~20× on FY27E EPS ~$10.40 → sentiment normalizes.~$240 (+67%)
Base (our anchor)Guidance roughly holds — FY27E adjusted EPS ~$10.40, high-single-digit recurring growth; a durable low-teens compounder with 40% ROE earns a de-rated but fair ~18×.~$187 (+30%)
BearRecurring growth slips toward ~5%, event-driven softens, buybacks slow; the market keeps treating it as a low-growth utility and holds the multiple near today's ~12× on FY27E EPS.~$120 (−17%)

Synthos fair value = the base case, ~$187 (+30%), with the full $120–$240 span as the honest range. Our base sits below the Street's $210 consensus (we apply a more conservative post-de-rating multiple) and our bear is below the Street's $165 low (we take the "utility, not growth" re-rating risk seriously). This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BR is a quality compounder with low exponential potential:

Exponential Potential: Low (3/10). Own BR for durable ~10% EPS compounding + dividend + buyback at a de-rated price, not for a fast multibagger. A small, accelerating name with these returns would score 8–9; BR's maturity and decelerating top line cap it at 3.

5. Financials (real numbers — FMP annual/quarterly)

6. Valuation — priced in or room?

After the ~46% drawdown, BR is no longer expensive: 15.3× trailing GAAP EPS, ~15× FY26E, 14× FY27E, ~10× FY30E, EV/sales 2.7×, EV/EBITDA 10.0×, FCF yield ~7.8%, dividend yield ~2.7% (payout ~39%). For a business with 40% ROE, ~90%+ recurring/visible revenue, and low-teens EPS growth, that is a below-historical multiple — BR spent much of the last decade at 20–28× earnings. The bear's rebuttal is that the de-rating is deserved: growth is only mid-single-digit on the top line, and the market may permanently reclassify it from "compounder" to "financial utility," holding the multiple near 12–15×.

Our base case applies a ~18× multiple to FY27E EPS ~$10.40 → ~$187 (+30%) — a partial, not full, re-rating. Street targets (context): consensus $210, high $257, low $165 — our $187 base is more conservative than consensus because we don't assume a full return to the old multiple. Not a deep-value screamer, but a reasonable price for durable quality — a quality-compounder-at-a-discount buy rather than a growth buy.

7. Technicals (from the tech block)

8. Moat & competitive position

Broadridge's moat is entrenchment through mission-critical, high-switching-cost infrastructure. In investor communications it is effectively the industry utility for US shareholder proxy distribution and voting — a regulated, network-effect position that is extraordinarily hard to displace because it sits between issuers, brokers, and millions of investors. In trade processing (GTO), multi-year contracts, deep systems integration, and the operational risk of switching a settlement engine create very sticky, recurring, high-retention revenue (retention historically ~98%+). The asset-light model (capex ~1% of revenue) and 40% ROE reflect that moat.

The limits: it's a mature, share-dominant position, so growth comes from digitization, cross-sell, position growth (equity/fund account growth), and M&A rather than a wide-open TAM. Threats are secular (long-run shift away from paper/distribution revenue — though management is converting this to higher-margin digital) and client-concentration (a handful of large banks/brokers).

Peer set (market cap, from FMP — an imperfect IT-Services comp group, not pure-play analogs): Jabil $35.8B, Teledyne $30.2B, Zoom $25.6B, HP Inc. $20.1B, Wipro $19.8B, CDW $17.0B, Flex $50.1B, CGI $14.4B, Leidos $13.7B, Gartner $9.1B. None is a true proxy/securities-processing comp; Broadridge's closest real peers (SS&C, DTCC-adjacent processors) aren't in this list. Judge BR on its own recurring-revenue economics rather than this group.

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): recurring-revenue growth slipping below ~5% cc; FY27 guidance for adjusted-EPS growth below high-single-digits; a break to new lows below ~$135 on heavy volume; or FCF conversion deteriorating.

11. Key risks

12. Verdict, position sizing & monitoring

Buy — Tactical. Broadridge is a high-quality, entrenched financial-infrastructure compounder — 40% ROE, ~$1.06B FCF, sticky recurring revenue, management guiding 10–12% adjusted-EPS growth — that has been marked down ~46% into a genuinely reasonable ~15× forward multiple. The fundamentals support a base-case fair value of ~$187 (+30%). But this is Tactical, not Core, for two honest reasons: (1) there is zero expert coverage in our KB — no conviction-track corroboration, so the call is purely quant/fundamental; and (2) the technicals are in a downtrend (death cross, near 52-week lows), so the market is still repricing it and a value trap is possible.


Provenance & disclosures